Show simple item record

Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

Authordc.contributor.authorSantolaya, María Elena 
Authordc.contributor.authorO'Ryan Gallardo, Miguel 
Authordc.contributor.authorValenzuela, María Teresa 
Authordc.contributor.authorPrado, Valeria 
Authordc.contributor.authorVergara, Rodrigo F. 
Authordc.contributor.authorMuñoz, Alma 
Authordc.contributor.authorToneatto, Daniela 
Authordc.contributor.authorGraña, Gabriela 
Authordc.contributor.authorWang, Huajun 
Authordc.contributor.authorDull, Peter M. 
Admission datedc.date.accessioned2019-01-29T13:56:12Z
Available datedc.date.available2019-01-29T13:56:12Z
Publication datedc.date.issued2013
Cita de ítemdc.identifier.citationHuman Vaccines & Immunotherapeutics 9:11, 2304–2310; November 2013
Identifierdc.identifier.issn2164554X
Identifierdc.identifier.issn21645515
Identifierdc.identifier.other10.4161/hv.25505
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/160091
Abstractdc.description.abstractWe previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero®), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. participants in this extension study provided an additional blood sample 18-24 mo after last vaccine dose, to assess persistence of serum bactericidal activity with human complement (hSBA), and to compare with age-matched 4CMenB-naïve controls. In the original study, one month after one 4CMenB dose, 93% of subjects had seroprotective hSBA titers (≥4) against indicator serogroup B strains for individual vaccine antigens (fHbp, NadA and NZoMV), increasing to ~100% after two or three doses. After 18-24 mo, 62-73% of subjects given one dose had titers ≥4 against the three antigens, significantly lower rates than after two (77-94%) or three (86-97%) doses. only proportions with titers ≥ 4 against NZoMV were significantly different between the two (77%) and three (90%, p < 0.0001) dose gr
Lenguagedc.language.isoen
Publisherdc.publisherTaylor & Francis
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
Sourcedc.sourceHuman Vaccines and Immunotherapeutics
Keywordsdc.subjectAdolescents
Keywordsdc.subjectAntibodies
Keywordsdc.subjectMeningococcal
Keywordsdc.subjectPersistence
Keywordsdc.subjectSerogroup B
Keywordsdc.subjectVaccine
Títulodc.titlePersistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorlaj
Indexationuchile.indexArtículo de publicación SCOPUS
uchile.cosechauchile.cosechaSI


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile